[Skip to Navigation]
Comment & Response
January 2019

Use of Combination Systemic-Intratumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas—Reply

Author Affiliations
  • 1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida
  • 2Department of Dermatology and Cutaneous Surgery, Sylvester Comprehensive Cancer Center, Miami, Florida
  • 3Treasure Coast Dermatology, Port St Lucie, Florida
JAMA Dermatol. 2019;155(1):124-125. doi:10.1001/jamadermatol.2018.3651

In Reply We thank Dr Brunet-Possenti and her colleagues for their interest and thoughtful comments on our article.1 In that report, we described using a combination of systemic and intratumoral delivery of the 9-valent human papillomavirus (HPV) vaccine to treat a woman in her 90s with multiple cutaneous squamous cell carcinomas (SCCs). This novel approach was followed by complete regression of all tumors 11 months after the first intratumoral injection of the vaccine. This readily available vaccine was well tolerated, and at last follow-up, the patient remained free of tumors. To our knowledge, this is the first report suggesting that the HPV vaccine may have therapeutic utility for SCCs.

Add or change institution